 37 PM / Updated 19 minutes ago BRIEF-Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als Reuters Staff 
Jan 3 (Reuters) - Pfizer Inc: 
* SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS 
* SANGAMO THERAPEUTICS​ - CO, ‍PFIZER ANNOUNCED COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS 
* SANGAMO THERAPEUTICS INC - UNDER TERMS OF COLLABORATION AGREEMENT, SANGAMO WILL RECEIVE A $12 MILLION UPFRONT PAYMENT FROM PFIZER 
* SANGAMO THERAPEUTICS INC - UNDER AGREEMENT, CO ‍WILL BE RESPONSIBLE FOR DEVELOPMENT OF ZFP-TF CANDIDATES​ 
* SANGAMO - UNDER TERMS ELIGIBLE TO RECEIVE POTENTIAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS UP TO $150 MILLION, TIERED ROYALTIES ON NET SALES 
* SANGAMO - UNDER DEAL,‍PFIZER OPERATIONALLY,FINANCIALLY RESPONSIBLE FOR RESEARCH,DEVELOPMENT,COMMERCIALIZATION FOR C9ORF72 ZFP-TF,RESULTING PRODUCTS Source text for Eikon: Further company coverage: